Research indicates that Ischemia-Modified Albumin levels significantly increase as humans age. Specifically, a recent study examined serum oxidative stress markers across young, middle-aged, and elderly populations. Consequently, findings suggest that advanced age correlates with higher IMA concentrations. This reflects potential systemic oxidative changes occurring over the lifespan.

The investigators utilized the albumin cobalt binding assay to measure the protein's metal-binding capacity. In addition, they calculated the IMA/albumin ratio (IMAR) to provide a more standardized assessment. Notably, the elderly group (73-99 years) exhibited markedly higher values compared to younger cohorts. Therefore, aging independently influences the structural integrity of serum albumin through oxidative modifications.

Interpreting Ischemia-Modified Albumin levels in Geriatrics

Clinicians must account for these age-related baseline shifts when evaluating acute conditions. Using a single cutoff for all adults may lead to diagnostic inaccuracies. Furthermore, the IMA/albumin ratio serves as a sensitive indicator of chronic oxidative stress in older patients. However, further research is required to establish definitive reference ranges for diverse populations.

Frequently Asked Questions

Why do IMA levels increase in the elderly?

As individuals age, systemic oxidative stress naturally increases while antioxidant defenses decline. This environmental change causes the N-terminal end of albumin to modify, leading to higher Ischemia-Modified Albumin levels.

What is the IMA/albumin ratio (IMAR)?

The IMAR is a calculated value that adjusts the IMA level relative to the total serum albumin concentration. It provides a more accurate representation of oxidative stress, especially in patients with varying albumin levels.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Teselkin YO et al. The Level of Ischemia-Modified Albumin in Healthy Individuals of Different Age Groups. Bull Exp Biol Med. 2026 Mar 10. doi: 10.1007/s10517-026-06607-y. PMID: 41806345.

Sbarouni E et al. Ischemia-modified albumin: an overview. Hellenic J Cardiol. 2011;52(4):298-302.

Piwowar A. Ischemia-modified albumin (IMA) – a marker with many faces. Adv Clin Exp Med. 2010;19(4):411-421.